Your browser doesn't support javascript.
loading
Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes.
Leong, Samuel Liwei; Murdolo, Lawton; Maddumage, Janesha C; Koutsakos, Marios; Kedzierska, Katherine; Purcell, Anthony W; Gras, Stephanie; Grant, Emma J.
Afiliação
  • Leong SL; Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS) La Trobe University Bundoora VIC Australia.
  • Murdolo L; Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment (SABE) La Trobe University Bundoora VIC Australia.
  • Maddumage JC; Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS) La Trobe University Bundoora VIC Australia.
  • Koutsakos M; Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment (SABE) La Trobe University Bundoora VIC Australia.
  • Kedzierska K; Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS) La Trobe University Bundoora VIC Australia.
  • Purcell AW; Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment (SABE) La Trobe University Bundoora VIC Australia.
  • Gras S; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity University of Melbourne Melbourne VIC Australia.
  • Grant EJ; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity University of Melbourne Melbourne VIC Australia.
Clin Transl Immunology ; 13(5): e1509, 2024.
Article em En | MEDLINE | ID: mdl-38737448
ABSTRACT

Objectives:

Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.

Methods:

Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*1801 molecule.

Results:

Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*1801+ individuals and confirmed their HLA-B*1801 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA-B*1801-restricted NP219 peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*1801 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*1801 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.

Conclusion:

Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*1801-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Clin Transl Immunology Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Clin Transl Immunology Ano de publicação: 2024 Tipo de documento: Article